Semaglutide and Preoperative Residual Gastric Volumes

Launched by UNIVERSITY OF CALGARY · Feb 8, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how the medication semaglutide affects the amount of food or liquid still in the stomach before surgery. Some patients taking semaglutide may have a higher risk of a problem called pulmonary aspiration, which happens when stomach contents enter the lungs. This can occur even if patients follow the usual fasting guidelines before surgery. The researchers want to use a special ultrasound technique to measure how much is left in the stomach of patients who have been fasting, to see if those on semaglutide have more residual stomach contents than those not on the medication.

To participate in this trial, you need to be an adult over 18 years old who is scheduled for an elective surgery and has followed the fasting instructions. The study will include both patients taking semaglutide for weight management or diabetes and those who are not taking it. If you join, you can expect to have your stomach volume measured before your surgery, which will help the researchers understand more about how this medication affects gastric emptying. This study aims to provide better safety guidelines for patients undergoing surgery while on semaglutide.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • all elective surgical patients (\> 18 years of age)
• • followed institutional fasting protocol for surgery
• • patients taking GLP-1 receptor agonist (subcutaneous for weight management and/or blood glucose control in type II diabetes mellitus, N = 45)
• • patients not taking GLP-1 receptor agonist (N =45)
• Exclusion Criteria:
• • confounding delayed gastric emptying due to pregnancy
• • previous esophageal or gastric operation
• • etiologies at increased risk for delayed gastric emptying (hiatal hernia, Parkinson's disease, scleroderma, multiple sclerosis, and amyloidosis)
• • on medication that could potentially cause gastroparesis or delayed gastric or intestinal emptying (opioids, proton pump inhibitors, tricyclic antidepressants, calcium channel blockers, antipsychotic medications, loperamide, diphenoxylate, oxybutynin, hyoscine butylbromide, scopolamine, promethazine, glycopyrrolate, atropine, chlordiazepoxide, and lithium)